Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.

Saved in:
Bibliographic Details
Title: Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.
Authors: Touzeau C; Service d'Hématologie, Centre Hospitalier Universitaire de Nantes, Nantes Université, 5 All. de l'Île Gloriette, 44000, Nantes, France. Cyrille.TOUZEAU@chu-nantes.fr.; Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, INSERM, Centre National de la Recherche Scientifique, Université d'Angers, Université de Nantes, Nantes, France. Cyrille.TOUZEAU@chu-nantes.fr.; Site de Recherche Intégrée sur le Cancer, Imaging and Longitudinal Investigations to Ameliorate Decision-Making (ILIAD), French National Cancer Institute-French Ministry of Health-INSERM, 12558, Nantes, France. Cyrille.TOUZEAU@chu-nantes.fr., Lipe B; University of Rochester Medical Center, Rochester, NY, USA., Khan AM; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Dhakal B; Medical College of Wisconsin, Milwaukee, WI, USA., Nair S; Johnson & Johnson, Beerse, Belgium., He J; Johnson & Johnson, Raritan, NJ, USA., Mendes J; Johnson & Johnson, Raritan, NJ, USA., Lee S; Johnson & Johnson, Raritan, NJ, USA., Lonardi C; Johnson & Johnson, Buenos Aires, Argentina., Slaughter A; Johnson & Johnson, Zug, Switzerland., Lendvai N; Johnson & Johnson, Raritan, NJ, USA., Schecter JM; Johnson & Johnson, Raritan, NJ, USA., Chen D; Johnson & Johnson, Shanghai, China., Zhao M; IQVIA, Shanghai, China., Yeh TM; Johnson & Johnson, Raritan, NJ, USA., Leleu X; CHU Poitiers, Poitiers, France., Puig N; Centro de Investigación del Cancer, Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain., Dytfeld D; Poznan University of Medical Sciences, Poznań, Poland., Zamagni E; University of Bologna, Bologna, Italy., Weisel K; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Karlin L; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France., Delforge M; University of Leuven, Leuven, Belgium., Corradini P; Divisione di Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Milano, Milan, Italy., Mina R; The Division of Hematology, AOU Citt. della Salute e della Scienza di Torino, and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy., Roeloffzen W; University Medical Center Groningen, Groningen, Netherlands., Sidana S; Stanford University School of Medicine, Stanford, CA, USA.
Source: Advances in therapy [Adv Ther] 2025 Oct; Vol. 42 (10), pp. 5023-5041. Date of Electronic Publication: 2025 Aug 06.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1865-8652
DOI:10.1007/s12325-025-03308-2